Inspire Medical Systems (NYSE:INSP) Issues FY 2026 Earnings Guidance

Inspire Medical Systems (NYSE:INSP) updated its FY 2026 earnings guidance on Monday. The company provided earnings per share guidance of 1.050-1.450 for the period, compared to the consensus estimate of 0.910. The company issued revenue guidance of $835.0 million-$875.0 million, compared to the consensus revenue estimate of $848.9 million.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on INSP shares. Piper Sandler cut Inspire Medical Systems from an “overweight” rating to a “neutral” rating and reduced their target price for the stock from $85.00 to $55.00 in a report on Tuesday, May 5th. UBS Group started coverage on Inspire Medical Systems in a report on Tuesday, July 28th. They set a “sell” rating and a $39.00 price target for the company. Stifel Nicolaus decreased their price objective on Inspire Medical Systems from $70.00 to $65.00 and set a “buy” rating on the stock in a report on Tuesday, May 5th. Evercore downgraded Inspire Medical Systems from an “outperform” rating to an “in-line” rating and set a $40.00 target price for the company. in a research report on Tuesday, June 23rd. Finally, Wells Fargo & Company reduced their price target on shares of Inspire Medical Systems from $70.00 to $56.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 5th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, thirteen have given a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $73.28.

Inspire Medical Systems Price Performance

Shares of Inspire Medical Systems stock traded up $2.01 on Monday, reaching $52.22. The company had a trading volume of 982,653 shares, compared to its average volume of 1,163,664. The firm has a market cap of $1.50 billion, a price-to-earnings ratio of 11.63, a P/E/G ratio of 5.08 and a beta of 0.71. The firm’s 50-day moving average price is $45.98 and its two-hundred day moving average price is $55.45. Inspire Medical Systems has a 1 year low of $38.91 and a 1 year high of $147.03.

Inspire Medical Systems (NYSE:INSP) last released its quarterly earnings results on Monday, August 3rd. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.38. The company had revenue of $200.58 million for the quarter, compared to analyst estimates of $194.72 million. Inspire Medical Systems had a return on equity of 10.35% and a net margin of 14.33%.Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. As a group, analysts anticipate that Inspire Medical Systems will post 0.93 EPS for the current year.

Hedge Funds Weigh In On Inspire Medical Systems

A number of large investors have recently made changes to their positions in INSP. Wellington Management Group LLP bought a new position in Inspire Medical Systems in the 4th quarter valued at $203,929,000. Deerfield Management Company L.P. lifted its position in shares of Inspire Medical Systems by 648.4% during the third quarter. Deerfield Management Company L.P. now owns 1,047,694 shares of the company’s stock worth $77,739,000 after purchasing an additional 907,694 shares during the last quarter. Morgan Stanley lifted its position in shares of Inspire Medical Systems by 179.5% during the fourth quarter. Morgan Stanley now owns 1,259,762 shares of the company’s stock worth $116,188,000 after purchasing an additional 809,121 shares during the last quarter. Fuller & Thaler Asset Management Inc. purchased a new stake in shares of Inspire Medical Systems during the fourth quarter valued at $61,619,000. Finally, Balyasny Asset Management L.P. boosted its stake in shares of Inspire Medical Systems by 16,504.3% during the third quarter. Balyasny Asset Management L.P. now owns 614,359 shares of the company’s stock valued at $45,585,000 after purchasing an additional 610,659 shares during the period. 94.91% of the stock is owned by hedge funds and other institutional investors.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.